Jie Mu

Jie Mu

Auto-generated profile, based on publicly available information

Jie Mu

Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
BDBallachanda N. Devaiah
Ballachanda N. Devaiah
JMJie Mu
Jie Mu
BABen Akman
Ben Akman
SUSheetal Uppal
Sheetal Uppal
JWJocelyn D. Weissman
Jocelyn D. Weissman
DSDinah S. Singer
Dinah S. Singer
The protooncogene MYC regulates a variety of cellular processes, including proliferation and metabolism. Maintaining MYC at homeostatic levels is critical to normal cell function; overexpression drives many cancers. MYC stability is regulated through phosphorylation: phosphorylation at Thr58 signals degradation while Ser62 phosphorylation leads to its stabilization and functional activation. The bromodomain protein 4 (BRD4) is a transcriptional and epigenetic regulator with intrinsic kinase and histone acetyltransferase (HAT) activities that activates transcription of key protooncogenes, including MYC . We report that BRD4 phosphorylates MYC at Thr58, leading to MYC ubiquitination and degradation, thereby regulating MYC target genes. Importantly, BRD4 degradation, but not inhibition, results in increased levels of MYC protein. Conversely, MYC inhibits BRD4’s HAT activity, suggesting that MYC regulates its own transcription by limiting BRD4-mediated chromatin remodeling of its locus. The MYC stabilizing kinase, ERK1, regulates MYC levels directly and indirectly by inhibiting BRD4 kinase activity. These findings demonstrate that BRD4 negatively regulates MYC levels, which is counteracted by ERK1 activation.